4.2 Review

New molecular insights into osteosarcoma targeted therapy

Journal

CURRENT OPINION IN ONCOLOGY
Volume 25, Issue 4, Pages 398-406

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e3283622c1b

Keywords

genetic aberration; microRNA; molecular target; osteosarcoma; pathogenesis

Categories

Funding

  1. University Cancer Foundation via the Sister Institution Network Fund (SINF) at the Tianjin Medical University Cancer Institute & Hospital (TMUCIH
  2. Fudan University Shanghai Cancer Center (FUSCC)
  3. University of Texas MD Anderson Cancer Center (UT MDACC)
  4. Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) in China [IRT1076]

Ask authors/readers for more resources

Purpose of reviewRecent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets.Recent findingsThe genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-/, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-B ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets.SummaryThese translational studies in osteosarcoma have identified new molecular targets for osteosarcoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available